Risk factors of developing irreversible cranial ischemic complications in giant cell arteritis. A prospective study of 178 cases;Facteurs prédictifs de complications céphaliques ischémiques irréversibles au cours de la maladie de horton: Étude prospective sur 178 patients

Revue de Medecine Interne

Volumn 22, Issue 1, 2001, Pages 30-41

  Liozon, E ^a   Herrmann, F R ^b   Ly, K ^a   Jauberteau, M O ^a   Loustaud, V ^a   Soria, P ^a   Robert, P Y ^a   Liozon, F ^a   Vidal, E ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Giant cell arteritis; Inflammatory response; Ischemic complications; Polymyalgia rheumatica; Risk factors

Indexed keywords

FIBRINOGEN;

AGED; ARTICLE; BLINDNESS; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; GIANT CELL ARTERITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RISK FACTOR; THROMBOCYTE COUNT;

EID: 0035142944     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)00283-6     Document Type: Article

References (55)

1. Ophtalmic complications of giant cell arteritis
2. Ophtalmic features of giant cell arteritis
3. Neurologic aspects of temporal arteritis
4. Giant cell arteritis: A review of 35 cases
5. Ocular lesions of the temporal arteritis
6. Temporal arteritis
7. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings
8. Visual prognosis in giant cell arteritis
9. Giant cell arteritis
10. Neurologic disease in biopsy-proven giant cell (temporal) arteritis
11. Pronostic de l'artérite temporale traitée. Étude rétrospective de 87 observations
12. Manifestations of giant cell arteritis
13. Temporal arteritis. A 25-year epidemiologic, clinical and pathologic study
14. Manifestations ophtalmologiques de la maladie de Horton
15. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision
16. Giant cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients
17. Clinical features in patients with permanent visual loss due to biopsyproven giant cell arteritis
18. Risk factors and predictive model of giant cell arteritis in polymyalgia rheumatica
19. Risk factors for thrombotic events in giant cel arteritis and polymyalgia rheumatica
20. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis
21. Permanent visual loss and cerebrovascular accidents in giant cell arteritis
22. Ocular manifestations of giant cell arteritis
23. Thrombocytosis and ischaemic complications in giant cell arteritis
24. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis
25. No association between the inflammatory response and the risk of developing irreversible cranial ischemic complications: Comment on the article by Cid et al
26. L'artérite temporale de Horton. Étude anatomopathologique en microscopie optique
27. The American College of Rheumatology 1990: Criteria for the classification of giant cell arteritis
28. Occult temporal arteritis
29. Ocular manifestations of occult giant cell arteritis
30. The visual prognosis of temporal arteritis
31. Les ædèmes ischémiques de la tête du nerf optique dans la maladie de Horton
32. La place du doppler temporal dans le diagnostic des complications ophtalmologiques de la maladie de Horton
33. Intérêt du doppler artériel dans la maladie de Horton
34. Temporal arteritis and sensorineural hearing loss
35. Giant cell arteritis. Clinical features and involvement of different organs
36. Steroid-responsive hearing loss in giant cell arteritis
37. Incidence saisonnière de la maladie de Horton: Que conclure?
38. La maladie de Horton
39. Masticatory muscle pain: An important indicator of giant cell arteritis
40. Disease pattern in cranial ans large-vessel giant cell arteritis
41. Giant cell arteritis with normal sedimentation rate
42. Giant cell arteritis. A case with unusual neurologic manifestations and a normal sedimentation rate
43. Giant cell arteritis with normal erythrocyte sedimentation rate. Case report and review of the literature
44. Association between the inflammatory response and the risk of developing irreversible cranial ischemic complications: Comments on the article by Cid et al. and the letter of Nesher and al
45. Protéines de l'inflammation dans la maladie de Horton. Étude prospective sur 25 patients
46. Giant cell arteritis: Validity and reliability of various diagnostic criteria
47. Giant cell arteritis is a T cell-dependent disease
48. Disease patterns and tissue cytokine profiles in giant cell arteritis
49. Giant cell arteritis - A molecular approach to the multiple facets of the syndrome
50. IFN-gamma in combinaison with IL-3 accelerates platelet recovery in mice with 5-fluorouracyl-induced marrow aplasia
51. Interferon-gamma and human megakaryopoiesis
52. Megakaryocytic differentiation of HIMeg-1 cells induced by interferon gamma and tumour necrosis factor alpha but not by thrombopoietin
53. Low flow enhances platelet activation after acute experimental arterial injury
54. Thrombocytosis and giant cell arteritis
55. Complications oculaires de la maladie de Horton